Endometrial Carcinoma, Genital Neoplasms, Female, Uterine Cervical Neoplasms
Conditions
Brief summary
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.
Detailed description
This is a mixed-methods survey study including a 2-phased sequential-explanatory design: Phase 1, Qualitative interview will be done first to explore the treatment decision factors, treatment experiences and unmet needs during post treatment surveillance, to provide components and inform the quantitative data collection. Phase 2, quantitative survey to collect data on a larger scale and allow a statistical generation of the qualitative findings.
Interventions
OTHERinterview
30 for Qualitative interview and 750 for quantitative survey
Sponsors
Tongji Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 or older * Newly diagnosed stage III or IV CC or EC * Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis. * Told by their physician that their disease is stable. * Patients must have informed consent form (ICF) signed for the study.
Exclusion criteria
* Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor. * Previously participated in or participating in a clinical trial. * Patients who received another line of therapy after initial therapy. * Unable or unwilling to provide informed consent. * Not fluent in local language. * Indicates or exhibits hearing difficulties, which would make a conversation challenging.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment decision making | 1 day. At the time of the interview. | 1. Information seeking in treatment decision 2. Treatment decision making factors 3. Clinical trial awareness |
| Initial treatment experiences | 1 day. At the time of the interview. | 1. Influence of treatment on daily life and work 2. Information and education during treatment 3. Coordination of care 4. Overall impression on care received and doctor/nurses' availability |
| Unmet needs and gaps from diagnosis to post-treatment surveillance | 1 day. At the time of the interview. | 1. Psychological and emotional needs 2. Social support needs 3. Healthcare needs 4. Gaps during follow-up care |
Countries
China
Contacts
Primary ContactGang Chen
Outcome results
None listed